Background: Patients on renal replacement therapy face many dietary limitations, and cheese is often limited because of its high phosphate content; we have developed cheese with added calcium carbonate (CaCO3) to provide patients with a nutritional opportunity while improving their phosphate control. Methods: The present double-blind crossover study was aimed to compare the new modified cheese with an equivalent standard product in 16 patients. The increase in inter-dialysis phosphorus (ΔP) and pre-dialysis calcium were used as the primary endpoints for efficacy and safety. Results: The median ΔP (and IQR) was significantly lower with the modified cheese compared with the standard product: 2.5 (1.9–2.9) mg/dL vs. 2.7 (2.2–3.4) mg/dL, respectively (p < 0.02). No difference was observed in pre-dialysis serum calcium levels. Conclusions: The described modified cheese may represent an interesting means of overcoming some of the dietary limitations in patients on dialysis to help them achieve better nutrition and quality of life. Graphic abstract: [Figure not available: see fulltext.].

Calcium carbonate-enriched cheese to improve nutrition, compliance and phosphorus control in patients on kidney replacement therapy / G. Ardissino, R. Matta, M. Patricelli, V. Capone, A. Leoni, A. Groppelli, S. Vettoretti, L. Pavone, E. Margiotta, A. Brancadoro, E. Grimaldi, I. Cropanese, F. Raffiotta, P. Messa, G. Montini. - In: JN. JOURNAL OF NEPHROLOGY. - ISSN 1121-8428. - 35:1(2022 Jan), pp. 305-309. [10.1007/s40620-021-01102-1]

Calcium carbonate-enriched cheese to improve nutrition, compliance and phosphorus control in patients on kidney replacement therapy

G. Ardissino
;
P. Messa
Penultimo
;
G. Montini
Ultimo
2022

Abstract

Background: Patients on renal replacement therapy face many dietary limitations, and cheese is often limited because of its high phosphate content; we have developed cheese with added calcium carbonate (CaCO3) to provide patients with a nutritional opportunity while improving their phosphate control. Methods: The present double-blind crossover study was aimed to compare the new modified cheese with an equivalent standard product in 16 patients. The increase in inter-dialysis phosphorus (ΔP) and pre-dialysis calcium were used as the primary endpoints for efficacy and safety. Results: The median ΔP (and IQR) was significantly lower with the modified cheese compared with the standard product: 2.5 (1.9–2.9) mg/dL vs. 2.7 (2.2–3.4) mg/dL, respectively (p < 0.02). No difference was observed in pre-dialysis serum calcium levels. Conclusions: The described modified cheese may represent an interesting means of overcoming some of the dietary limitations in patients on dialysis to help them achieve better nutrition and quality of life. Graphic abstract: [Figure not available: see fulltext.].
Dialysis; Phosphorus; Renal replacement therapy; Secondary hyperparathiroidism
Settore MED/38 - Pediatria Generale e Specialistica
29-giu-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
Ardissino2021_Article_CalciumCarbonate-enrichedChees.pdf

accesso riservato

Descrizione: Articolo principale online first
Tipologia: Publisher's version/PDF
Dimensione 798.76 kB
Formato Adobe PDF
798.76 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Ardissino2022_Article_CalciumCarbonate-enrichedChees.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 783.46 kB
Formato Adobe PDF
783.46 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/878174
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact